A Bacterial Lifestyle Switch Provides Antibiotic Resistance
|
By LabMedica International staff writers Posted on 06 Jan 2016 |

Image: Light micrograph of Bacillus cereus in a small colony variant (SCV) (Photo courtesy of Markus Kranzler/Vetmeduni Vienna).
Researchers have reported for the first time that following contact with certain antibiotics the pathogenic Bacillus cereus can switch into a special slowed-down mode and form small colony variants (SVCs) that are difficult to diagnose and almost impossible to treat with certain antibiotics.
Bacillus cereus causes vomiting and diarrhea as well as systemic and local infections such as sepsis or eye infections. The newly discovered mechanism, from a study led by researchers from the Vetmeduni Vienna (University of Veterinary Medicine Vienna (Austria), provides an explanation for this and possibly other cases of antibiotic resistance.
B. cereus had so far been considered to be exclusively endospore-forming in response to harsh conditions. The new study discovered an alternative lifestyle in which B. cereus forms SCVs in response to exposure to aminoglycoside antibiotics. The B. cereus SCVs grow slower, have an altered metabolism, and provide resistance to aminoglycosides. “The bacterium protects itself against the harmful effects of the antibiotics by forming these SCVs. But B. cereus is usually treated with exactly those antibiotics which induce the SCV state. If an antibiotic triggers the formation of SCVs, it also triggers resistance,” explained first author Dr. Frenzel.
The discovery of this mechanism is of great significance for clinical practice and will require rethinking diagnostics and therapy. Traditional diagnostics are based on identification of metabolic features of B. cereus, but these tests do not detect SCVs. This may result in incorrect antibiotic therapies or even failed diagnoses. Molecular tests may be the only way to diagnose this form of B. cereus. Treating B. cereus infections using only aminoglycoside antibiotics could bear the risk of a prolonged infection. SCVs grow more slowly, but they still produce toxins that are harmful to the body. “In this case, a combination therapy with other antibiotic groups is advisable,” Dr. Frenzel recommends.
Another bacterium, Staphylococcus aureus, also forms SCVs, but is capable of reverting to its original state. For B. cereus, the SCV form appears to be final, suggesting a new mechanism. “We believe that the SCV formation in B. cereus functions differently than in S. aureus,” said coauthor Dr. Ehling-Schulz.
“The ability to form SCVs appears to be of environmental significance for the bacteria,” said Dr. Frenzel, “B. cereus are soil-dwelling, and other microorganism in the soil produce antibiotics. Here, too, the formation of SCVs would be an advantage for the bacteria.”
The study, by Frenzel E, Kranzler M et al., was published December 8, 2015, in the journal mBio.
Related Links:
University of Veterinary Medicine Vienna
Bacillus cereus causes vomiting and diarrhea as well as systemic and local infections such as sepsis or eye infections. The newly discovered mechanism, from a study led by researchers from the Vetmeduni Vienna (University of Veterinary Medicine Vienna (Austria), provides an explanation for this and possibly other cases of antibiotic resistance.
B. cereus had so far been considered to be exclusively endospore-forming in response to harsh conditions. The new study discovered an alternative lifestyle in which B. cereus forms SCVs in response to exposure to aminoglycoside antibiotics. The B. cereus SCVs grow slower, have an altered metabolism, and provide resistance to aminoglycosides. “The bacterium protects itself against the harmful effects of the antibiotics by forming these SCVs. But B. cereus is usually treated with exactly those antibiotics which induce the SCV state. If an antibiotic triggers the formation of SCVs, it also triggers resistance,” explained first author Dr. Frenzel.
The discovery of this mechanism is of great significance for clinical practice and will require rethinking diagnostics and therapy. Traditional diagnostics are based on identification of metabolic features of B. cereus, but these tests do not detect SCVs. This may result in incorrect antibiotic therapies or even failed diagnoses. Molecular tests may be the only way to diagnose this form of B. cereus. Treating B. cereus infections using only aminoglycoside antibiotics could bear the risk of a prolonged infection. SCVs grow more slowly, but they still produce toxins that are harmful to the body. “In this case, a combination therapy with other antibiotic groups is advisable,” Dr. Frenzel recommends.
Another bacterium, Staphylococcus aureus, also forms SCVs, but is capable of reverting to its original state. For B. cereus, the SCV form appears to be final, suggesting a new mechanism. “We believe that the SCV formation in B. cereus functions differently than in S. aureus,” said coauthor Dr. Ehling-Schulz.
“The ability to form SCVs appears to be of environmental significance for the bacteria,” said Dr. Frenzel, “B. cereus are soil-dwelling, and other microorganism in the soil produce antibiotics. Here, too, the formation of SCVs would be an advantage for the bacteria.”
The study, by Frenzel E, Kranzler M et al., was published December 8, 2015, in the journal mBio.
Related Links:
University of Veterinary Medicine Vienna
Latest Microbiology News
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Channels
Clinical Chemistry
view channel
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read moreMolecular Diagnostics
view channel
AI-Powered Blood Test Detects Early Pancreatic Cancer with More Than 90% Accuracy
Pancreatic cancer is one of the most lethal cancers, often referred to as the “King of Cancers” because symptoms usually appear only at advanced stages. As a result, most patients are diagnosed late, and... Read more
AI-Powered Blood Test Flags Relapse Risk Earlier After Transplant
Relapse after allogeneic hematopoietic cell transplant is a major cause of mortality in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and standard monitoring can miss early warning signals.... Read more
World’s First Portable POC Test Simultaneously Detects Four Common STIs in One Hour
Sexually transmitted infections (STIs) often present with similar symptoms, making accurate diagnosis challenging without laboratory testing. Delays in identifying the exact infection can lead to inappropriate... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more








